Vinge advises Danish healthcare company Coloplast on its acquisition of Atos Medical, the global market leader in laryngectomy for EUR 2.155 billion (around DKK 16 billion) from PAI Partners, a global private equity firm headquartered in Paris. Closing of the transaction is subject to customary regulatory approvals and anticipated to occur in Q2 2021/22.

Vinge’s team primarily consisted of Matthias Pannier, Ulrich Ziche, Vilhelm Rondahl, Clara Sohlberg and Julia Hagelberg (M&A), Klara Secher and Axel Lennartsson (IP), Lisa Hörnqvist and Mario Saad (Agreements and IT), Karl-Hugo Engdahl and Karolina Fuhrman (GDPR), Tove Lövgren Frisk (Compliance), Jolinn Uhlin and Michaela Ådén (Banking & Financing), Elin Broman (Employment) and Lina Österberg and Ulf Pyk (Real Estate). Kromann Reumert acted as lead counsel for Coloplast.

Related

Vinge has advised Ingka Investments on its largest forestland acquisition

Ingka Investments, the investment arm of Ingka Group (the world’s largest IKEA retailer), has agreed to acquire approximately 153,000 hectares of land, mainly forestland, from Södra, Sweden’s largest forest owners’ association.
October 20, 2025

Vinge advises Procuritas on its acquisition of Parkman

Vinge has advised Procuritas Capital Investors VII (“Procuritas”) in connection with the acquisition of Parkman i Sverige AB (“Parkman”), a growing Swedish tech-enabled parking operator that provides parking management solutions. As part of the transaction, Indigo Management AS becomes a minority owner of the company.
October 20, 2025

Vinge has advised Eleda in connection with the acquisition of Nordic Infrastructure Group AS (“Qben Rail”)

Qben Infra AB and ININ Group AS, which is majority owned by Qben Infra AB, have entered into a share purchase agreement with Eleda through Eleda’s subsidiary Eleda Norge AS (“Eleda”), to divest the Qben Rail platform to Eleda for a total enterprise value of up to NOK 850 million, including an earn out of up to NOK 65 million. Completion of the transaction is subject to customary closing conditions, including approval from the Swedish Inspectorate of Strategic Products and the Norwegian Competition Authority.
October 17, 2025